Results 21 to 30 of about 20,539 (229)

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study

BMC Pulmonary Medicine, 2020
Background Treatment of pulmonary sarcoidosis is recommended in case of significant symptoms, impaired or deteriorating lung function. Evidence-based treatment recommendations are limited and largely based on expert opinion.
Vivienne Kahlmann, Montse Janssen Bonás, Catharina C. Moor, Coline H. M. van Moorsel, Mirjam Kool, Raisa Kraaijvanger, Jan C. Grutters, Mayka Overgaauw, Marcel Veltkamp, Marlies S. Wijsenbeek, Collaborating investigators   +10 more
doaj   +1 more source

The MUC5B Promoter Polymorphism Associates With Severe COVID-19 in the European Population

Frontiers in Medicine, 2021
Background: Diversity in response on exposure to severe acute respiratory syndrome coronavirus 2 may be related to the innate immune response in the elderly.
Coline H. M. van Moorsel, Coline H. M. van Moorsel, Joanne J. van der Vis, Joanne J. van der Vis, Anna Duckworth, Chris J. Scotton, Claudia Benschop, Claudia Benschop, David Ellinghaus, David Ellinghaus, Henk J. T. Ruven, Marian J. R. Quanjel, Jan C. Grutters, Jan C. Grutters   +13 more
doaj   +1 more source

The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis

Frontiers in Medicine, 2021
Familial pulmonary fibrosis (FPF) is a monogenic disease most commonly involving telomere- (TERT) or surfactant- (SFTP) related mutations. These mutations have been shown to alter lymphocytic inflammatory responses, and FPF biopsies with histological ...
Aernoud A. van Batenburg, Matthijs F. M. van Oosterhout, Sebastiaan N. Knoppert, Sebastiaan N. Knoppert, Karin M. Kazemier, Karin M. Kazemier, Joanne J. van der Vis, Joanne J. van der Vis, Jan C. Grutters, Jan C. Grutters, Roel Goldschmeding, Coline H. M. van Moorsel, Coline H. M. van Moorsel   +12 more
doaj   +1 more source

Characterisation of Disease Patterns of Dermatomyositis with Different Initial Manifestations

International Journal of General Medicine, 2022
Yue Sun,1 Dai-Feng Li,2 Yin-Li Zhang,1 Xu Liang,1 Tian-Fang Li1 1Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, People’s Republic of China; 2Department of Orthopaedics, The First Affiliated Hospital ...
Sun Y, Li DF, Zhang YL, Liang X, Li TF
doaj  

Telomere shortening and DNA damage in culprit cells of different types of progressive fibrosing interstitial lung disease

ERJ Open Research, 2021
Pulmonary fibrosis is strongly associated with telomere shortening and increased DNA damage. Key cells in the pathogenesis involve alveolar type 2 (AT2) cells, club cells and myofibroblasts; however, to what extent these cells are affected by telomere ...
Aernoud A. van Batenburg, Karin M. Kazemier, Matthijs F.M. van Oosterhout, Joanne J. van der Vis, Jan C. Grutters, Roel Goldschmeding, Coline H.M. van Moorsel   +6 more
doaj   +1 more source

TEL-CTD-ILD study design.

, 2022
TEL-CTD-ILD study design.
Joanna Miłkowska-Dymanowska (12068075), Wojciech Jerzy Piotrowski (14305166), Maria Mozga (14305157), Ewa Miądlikowska (14305160), Adam Jerzy Białas (14305163), Sylwia Małysiak-Szpond (14305154)   +5 more
core   +1 more source

A rare case of anti-jo1 syndrome presenting as a interstitial lung disease

Journal of Association of Pulmonologist of Tamil Nadu, 2020
Antisynthetase syndrome is a rare entity and can be missed if not specifically looked in patients whose initial presentation is with Interstitial Lung Disease. Prognosis is altered when patients presenting with Interstitial Lung Disease.
A Kirubanandam, R Sridhar, R Narasimhan, V L Arulselvan   +3 more
doaj   +1 more source

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

Cells, 2021
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade® or Inflectra® to Flixabi® in patients with severe ...
Bas J. M. Peters, Anish Bhatoe, Adriane D. M. Vorselaars, Marcel Veltkamp   +3 more
doaj   +1 more source

SERUM BIOMARKERS IN INTERSTITIAL LUNG ABNORMALITIES AND FAMILIAL EARLY INTERSTITIAL LUNG DISEASE

Open Respiratory Archives
Introduction: Interstitial lung abnormalities (ILA) are incidental findings at thorax computed tomography in asymptomatic patients that could progress and could be sporadic (ILA) or with a genetic substrate (EARLY interstitial lung disease (ILD ...
Elsie Vera-Santiesteban, Marta Gabasa, Yasmina Gutiérrez-Rodríguez, Jose Palma-Rodríguez, Guadalupe Bermudo, Mireya Fuentes, Maria Molina-Molina, Vanesa Vicens-Zygmunt   +7 more
doaj   +1 more source

Clinical, molecular and immunohistochemical characterization of primary Lung Cancer developed in the context of Interstitial Lung Disease

, 2023
reservedBackground: ILD is a heterogeneous group of diffuse parenchymal lung diseases, some of which are known to present an independent risk factor for lung cancer. Particularly IPF has a well-established link with LC onset. Other ILDs, such as CTD-ILD,
SCORDARI, MATTEO
core